Loading...
XSES
T14
Market cap3.74bUSD
Dec 05, Last price  
3.23USD
1D
1.89%
1Q
10.24%
Jan 2017
269.14%
IPO
836.23%
Name

Tianjin Zhongxin Phrmctl Gp Cp Ltd

Chart & Performance

D1W1MN
XSES:T14 chart
P/E
5.84
P/S
1.78
EPS
3.91
Div Yield, %
1.03%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
0.88%
Revenues
7.31b
-11.14%
2,517,141,0002,149,968,0002,258,414,0002,365,338,0002,880,863,2603,473,471,2664,391,889,1475,129,925,9876,010,136,7287,086,879,2787,080,552,2386,178,821,7965,689,242,4966,358,622,3186,993,881,6976,603,652,0156,907,544,2568,249,249,5658,222,311,8497,306,736,058
Net income
2.23b
+125.94%
80,787,000-377,764,000-72,819,000182,080,000257,817,625293,287,101247,649,856441,299,096351,794,374357,800,340451,442,939422,423,006476,079,838561,679,706625,568,681661,704,350769,144,377861,793,906986,707,3772,229,334,236
CFO
925m
+34.30%
261,906,000-28,083,00020,131,000155,768,00083,407,791139,035,377173,880,27720,808,888213,435,404286,854,209360,583,419419,901,9090350,144,366495,488,678671,420,832852,401,231677,245,078688,487,880924,672,004
Dividend
Jul 02, 20240.03272458 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.
IPO date
Jun 06, 2001
Employees
4,913
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT